nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—HRH1—atherosclerosis	0.441	1	CbGaD
Trimipramine—CYP2C19—Rosuvastatin—atherosclerosis	0.0258	0.0701	CbGbCtD
Trimipramine—CYP2C19—Simvastatin—atherosclerosis	0.024	0.0652	CbGbCtD
Trimipramine—CYP2C19—Lovastatin—atherosclerosis	0.0235	0.0638	CbGbCtD
Trimipramine—CYP2D6—Niacin—atherosclerosis	0.023	0.0627	CbGbCtD
Trimipramine—CYP2C9—Rosuvastatin—atherosclerosis	0.0214	0.0583	CbGbCtD
Trimipramine—ABCB1—Ezetimibe—atherosclerosis	0.0208	0.0566	CbGbCtD
Trimipramine—CYP2C9—Simvastatin—atherosclerosis	0.0199	0.0542	CbGbCtD
Trimipramine—CYP2C9—Lovastatin—atherosclerosis	0.0195	0.053	CbGbCtD
Trimipramine—CYP2C9—Pravastatin—atherosclerosis	0.0195	0.053	CbGbCtD
Trimipramine—ABCB1—Simvastatin—atherosclerosis	0.0193	0.0526	CbGbCtD
Trimipramine—ABCB1—Pravastatin—atherosclerosis	0.0189	0.0515	CbGbCtD
Trimipramine—ABCB1—Lovastatin—atherosclerosis	0.0189	0.0515	CbGbCtD
Trimipramine—CYP2D6—Simvastatin—atherosclerosis	0.0182	0.0496	CbGbCtD
Trimipramine—CYP2D6—Lovastatin—atherosclerosis	0.0178	0.0485	CbGbCtD
Trimipramine—CYP2D6—Pravastatin—atherosclerosis	0.0178	0.0485	CbGbCtD
Trimipramine—CYP3A4—Ezetimibe—atherosclerosis	0.0125	0.0339	CbGbCtD
Trimipramine—CYP3A4—Rosuvastatin—atherosclerosis	0.0125	0.0339	CbGbCtD
Trimipramine—CYP3A4—Simvastatin—atherosclerosis	0.0116	0.0315	CbGbCtD
Trimipramine—CYP3A4—Pravastatin—atherosclerosis	0.0113	0.0308	CbGbCtD
Trimipramine—CYP3A4—Lovastatin—atherosclerosis	0.0113	0.0308	CbGbCtD
Trimipramine—HTR2A—arteriole—atherosclerosis	0.00156	0.169	CbGeAlD
Trimipramine—Nightmare—Rosuvastatin—atherosclerosis	0.00138	0.0142	CcSEcCtD
Trimipramine—Tingling sensation—Niacin—atherosclerosis	0.0013	0.0133	CcSEcCtD
Trimipramine—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00128	0.0132	CcSEcCtD
Trimipramine—Numbness—Pravastatin—atherosclerosis	0.00124	0.0127	CcSEcCtD
Trimipramine—Sensory loss—Pravastatin—atherosclerosis	0.00119	0.0122	CcSEcCtD
Trimipramine—Nightmare—Simvastatin—atherosclerosis	0.0011	0.0113	CcSEcCtD
Trimipramine—Gynaecomastia—Lovastatin—atherosclerosis	0.00109	0.0112	CcSEcCtD
Trimipramine—Gynaecomastia—Simvastatin—atherosclerosis	0.00102	0.0104	CcSEcCtD
Trimipramine—Nightmare—Pravastatin—atherosclerosis	0.000992	0.0102	CcSEcCtD
Trimipramine—Vascular purpura—Lovastatin—atherosclerosis	0.000985	0.0101	CcSEcCtD
Trimipramine—HTR2A—vein—atherosclerosis	0.000928	0.101	CbGeAlD
Trimipramine—Vascular purpura—Simvastatin—atherosclerosis	0.000922	0.00946	CcSEcCtD
Trimipramine—Gynaecomastia—Pravastatin—atherosclerosis	0.000919	0.00943	CcSEcCtD
Trimipramine—Purpura—Lovastatin—atherosclerosis	0.000915	0.00939	CcSEcCtD
Trimipramine—Purpura—Simvastatin—atherosclerosis	0.000856	0.00878	CcSEcCtD
Trimipramine—Vascular purpura—Pravastatin—atherosclerosis	0.000833	0.00855	CcSEcCtD
Trimipramine—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.000786	0.00807	CcSEcCtD
Trimipramine—Jaundice—Rosuvastatin—atherosclerosis	0.000781	0.00802	CcSEcCtD
Trimipramine—Purpura—Pravastatin—atherosclerosis	0.000773	0.00794	CcSEcCtD
Trimipramine—HTR1D—artery—atherosclerosis	0.000761	0.0826	CbGeAlD
Trimipramine—Eosinophilia—Lovastatin—atherosclerosis	0.000754	0.00774	CcSEcCtD
Trimipramine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.000751	0.00771	CcSEcCtD
Trimipramine—Eosinophilia—Ezetimibe—atherosclerosis	0.00074	0.00759	CcSEcCtD
Trimipramine—Urinary retention—Niacin—atherosclerosis	0.00072	0.00739	CcSEcCtD
Trimipramine—Eosinophilia—Simvastatin—atherosclerosis	0.000706	0.00724	CcSEcCtD
Trimipramine—Erectile dysfunction—Lovastatin—atherosclerosis	0.000702	0.0072	CcSEcCtD
Trimipramine—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000688	0.00706	CcSEcCtD
Trimipramine—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000666	0.00684	CcSEcCtD
Trimipramine—Erectile dysfunction—Simvastatin—atherosclerosis	0.000656	0.00674	CcSEcCtD
Trimipramine—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000653	0.0067	CcSEcCtD
Trimipramine—Jaundice—Ezetimibe—atherosclerosis	0.00065	0.00667	CcSEcCtD
Trimipramine—Arrhythmia—Rosuvastatin—atherosclerosis	0.000643	0.0066	CcSEcCtD
Trimipramine—Eosinophilia—Pravastatin—atherosclerosis	0.000638	0.00655	CcSEcCtD
Trimipramine—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000623	0.00639	CcSEcCtD
Trimipramine—Jaundice—Simvastatin—atherosclerosis	0.000619	0.00636	CcSEcCtD
Trimipramine—HTR2A—hindlimb—atherosclerosis	0.000616	0.067	CbGeAlD
Trimipramine—Erectile dysfunction—Niacin—atherosclerosis	0.000603	0.00619	CcSEcCtD
Trimipramine—Erectile dysfunction—Pravastatin—atherosclerosis	0.000593	0.00609	CcSEcCtD
Trimipramine—HTR1D—blood vessel—atherosclerosis	0.000593	0.0644	CbGeAlD
Trimipramine—Weight increased—Pravastatin—atherosclerosis	0.000586	0.00602	CcSEcCtD
Trimipramine—Stomatitis—Niacin—atherosclerosis	0.000569	0.00584	CcSEcCtD
Trimipramine—Jaundice—Niacin—atherosclerosis	0.000569	0.00584	CcSEcCtD
Trimipramine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000566	0.00581	CcSEcCtD
Trimipramine—Flushing—Lovastatin—atherosclerosis	0.000566	0.00581	CcSEcCtD
Trimipramine—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000563	0.00578	CcSEcCtD
Trimipramine—Myocardial infarction—Pravastatin—atherosclerosis	0.000563	0.00578	CcSEcCtD
Trimipramine—Jaundice—Pravastatin—atherosclerosis	0.00056	0.00575	CcSEcCtD
Trimipramine—Flushing—Ezetimibe—atherosclerosis	0.000555	0.0057	CcSEcCtD
Trimipramine—Isothipendyl—HRH1—atherosclerosis	0.000545	0.0922	CrCbGaD
Trimipramine—Alopecia—Lovastatin—atherosclerosis	0.000539	0.00553	CcSEcCtD
Trimipramine—Flushing—Simvastatin—atherosclerosis	0.000529	0.00543	CcSEcCtD
Trimipramine—HTR2A—appendage—atherosclerosis	0.000529	0.0574	CbGeAlD
Trimipramine—Alopecia—Ezetimibe—atherosclerosis	0.000529	0.00543	CcSEcCtD
Trimipramine—Hypoaesthesia—Niacin—atherosclerosis	0.000521	0.00535	CcSEcCtD
Trimipramine—Dysgeusia—Lovastatin—atherosclerosis	0.00052	0.00534	CcSEcCtD
Trimipramine—Confusional state—Rosuvastatin—atherosclerosis	0.000516	0.00529	CcSEcCtD
Trimipramine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000513	0.00527	CcSEcCtD
Trimipramine—Alopecia—Simvastatin—atherosclerosis	0.000504	0.00517	CcSEcCtD
Trimipramine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000501	0.00514	CcSEcCtD
Trimipramine—Vision blurred—Lovastatin—atherosclerosis	0.0005	0.00514	CcSEcCtD
Trimipramine—Tremor—Lovastatin—atherosclerosis	0.000497	0.00511	CcSEcCtD
Trimipramine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000493	0.00506	CcSEcCtD
Trimipramine—Tinnitus—Niacin—atherosclerosis	0.000488	0.00501	CcSEcCtD
Trimipramine—Dysgeusia—Simvastatin—atherosclerosis	0.000486	0.00499	CcSEcCtD
Trimipramine—Flushing—Niacin—atherosclerosis	0.000486	0.00499	CcSEcCtD
Trimipramine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000483	0.00496	CcSEcCtD
Trimipramine—Tinnitus—Pravastatin—atherosclerosis	0.000481	0.00494	CcSEcCtD
Trimipramine—Malaise—Lovastatin—atherosclerosis	0.000479	0.00491	CcSEcCtD
Trimipramine—Flushing—Pravastatin—atherosclerosis	0.000479	0.00491	CcSEcCtD
Trimipramine—Aceprometazine—HRH1—atherosclerosis	0.000471	0.0798	CrCbGaD
Trimipramine—Malaise—Ezetimibe—atherosclerosis	0.00047	0.00482	CcSEcCtD
Trimipramine—Vision blurred—Simvastatin—atherosclerosis	0.000468	0.0048	CcSEcCtD
Trimipramine—Arrhythmia—Niacin—atherosclerosis	0.000468	0.0048	CcSEcCtD
Trimipramine—Tremor—Simvastatin—atherosclerosis	0.000465	0.00478	CcSEcCtD
Trimipramine—Alopecia—Niacin—atherosclerosis	0.000463	0.00475	CcSEcCtD
Trimipramine—Insomnia—Rosuvastatin—atherosclerosis	0.000462	0.00475	CcSEcCtD
Trimipramine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000461	0.00473	CcSEcCtD
Trimipramine—Arrhythmia—Pravastatin—atherosclerosis	0.000461	0.00473	CcSEcCtD
Trimipramine—Palpitations—Ezetimibe—atherosclerosis	0.00046	0.00472	CcSEcCtD
Trimipramine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000459	0.00471	CcSEcCtD
Trimipramine—Alopecia—Pravastatin—atherosclerosis	0.000456	0.00468	CcSEcCtD
Trimipramine—Anxiety—Lovastatin—atherosclerosis	0.00045	0.00462	CcSEcCtD
Trimipramine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00045	0.00462	CcSEcCtD
Trimipramine—Hypertension—Ezetimibe—atherosclerosis	0.00045	0.00461	CcSEcCtD
Trimipramine—Malaise—Simvastatin—atherosclerosis	0.000448	0.0046	CcSEcCtD
Trimipramine—Discomfort—Lovastatin—atherosclerosis	0.000447	0.00458	CcSEcCtD
Trimipramine—Pheniramine—HRH1—atherosclerosis	0.000446	0.0755	CrCbGaD
Trimipramine—Dry mouth—Lovastatin—atherosclerosis	0.000442	0.00454	CcSEcCtD
Trimipramine—Dysgeusia—Pravastatin—atherosclerosis	0.00044	0.00451	CcSEcCtD
Trimipramine—Discomfort—Ezetimibe—atherosclerosis	0.000438	0.0045	CcSEcCtD
Trimipramine—Constipation—Rosuvastatin—atherosclerosis	0.000437	0.00449	CcSEcCtD
Trimipramine—Confusional state—Lovastatin—atherosclerosis	0.000437	0.00448	CcSEcCtD
Trimipramine—Methdilazine—HRH1—atherosclerosis	0.000437	0.0739	CrCbGaD
Trimipramine—Dry mouth—Ezetimibe—atherosclerosis	0.000434	0.00445	CcSEcCtD
Trimipramine—Vision blurred—Niacin—atherosclerosis	0.00043	0.00441	CcSEcCtD
Trimipramine—Confusional state—Ezetimibe—atherosclerosis	0.000429	0.0044	CcSEcCtD
Trimipramine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000424	0.00435	CcSEcCtD
Trimipramine—Vision blurred—Pravastatin—atherosclerosis	0.000423	0.00434	CcSEcCtD
Trimipramine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000421	0.00432	CcSEcCtD
Trimipramine—Anxiety—Simvastatin—atherosclerosis	0.000421	0.00432	CcSEcCtD
Trimipramine—Tremor—Pravastatin—atherosclerosis	0.000421	0.00432	CcSEcCtD
Trimipramine—Discomfort—Simvastatin—atherosclerosis	0.000418	0.00429	CcSEcCtD
Trimipramine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000417	0.00428	CcSEcCtD
Trimipramine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000416	0.00427	CcSEcCtD
Trimipramine—Anorexia—Lovastatin—atherosclerosis	0.000413	0.00424	CcSEcCtD
Trimipramine—Confusional state—Simvastatin—atherosclerosis	0.000409	0.00419	CcSEcCtD
Trimipramine—Urticaria—Rosuvastatin—atherosclerosis	0.000406	0.00417	CcSEcCtD
Trimipramine—Clofedanol—HRH1—atherosclerosis	0.000406	0.0687	CrCbGaD
Trimipramine—Oedema—Simvastatin—atherosclerosis	0.000405	0.00416	CcSEcCtD
Trimipramine—Malaise—Pravastatin—atherosclerosis	0.000405	0.00416	CcSEcCtD
Trimipramine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000404	0.00415	CcSEcCtD
Trimipramine—Palpitations—Niacin—atherosclerosis	0.000403	0.00414	CcSEcCtD
Trimipramine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000397	0.00407	CcSEcCtD
Trimipramine—Insomnia—Lovastatin—atherosclerosis	0.000392	0.00402	CcSEcCtD
Trimipramine—Paraesthesia—Lovastatin—atherosclerosis	0.000389	0.00399	CcSEcCtD
Trimipramine—Hypertension—Pravastatin—atherosclerosis	0.000388	0.00398	CcSEcCtD
Trimipramine—Anorexia—Simvastatin—atherosclerosis	0.000386	0.00397	CcSEcCtD
Trimipramine—Insomnia—Ezetimibe—atherosclerosis	0.000384	0.00395	CcSEcCtD
Trimipramine—Paraesthesia—Ezetimibe—atherosclerosis	0.000382	0.00392	CcSEcCtD
Trimipramine—Dyspepsia—Lovastatin—atherosclerosis	0.000381	0.00391	CcSEcCtD
Trimipramine—Anxiety—Pravastatin—atherosclerosis	0.000381	0.00391	CcSEcCtD
Trimipramine—Dry mouth—Niacin—atherosclerosis	0.00038	0.0039	CcSEcCtD
Trimipramine—HTR2A—artery—atherosclerosis	0.000378	0.041	CbGeAlD
Trimipramine—Discomfort—Pravastatin—atherosclerosis	0.000378	0.00388	CcSEcCtD
Trimipramine—Decreased appetite—Lovastatin—atherosclerosis	0.000377	0.00387	CcSEcCtD
Trimipramine—Dyspepsia—Ezetimibe—atherosclerosis	0.000374	0.00384	CcSEcCtD
Trimipramine—Fatigue—Lovastatin—atherosclerosis	0.000374	0.00383	CcSEcCtD
Trimipramine—Oedema—Niacin—atherosclerosis	0.000372	0.00382	CcSEcCtD
Trimipramine—Constipation—Lovastatin—atherosclerosis	0.000371	0.0038	CcSEcCtD
Trimipramine—Confusional state—Pravastatin—atherosclerosis	0.000369	0.00379	CcSEcCtD
Trimipramine—Decreased appetite—Ezetimibe—atherosclerosis	0.000369	0.00379	CcSEcCtD
Trimipramine—Asthenia—Rosuvastatin—atherosclerosis	0.000367	0.00377	CcSEcCtD
Trimipramine—Insomnia—Simvastatin—atherosclerosis	0.000367	0.00376	CcSEcCtD
Trimipramine—Oedema—Pravastatin—atherosclerosis	0.000366	0.00376	CcSEcCtD
Trimipramine—Fatigue—Ezetimibe—atherosclerosis	0.000366	0.00376	CcSEcCtD
Trimipramine—Paraesthesia—Simvastatin—atherosclerosis	0.000364	0.00374	CcSEcCtD
Trimipramine—Constipation—Ezetimibe—atherosclerosis	0.000363	0.00373	CcSEcCtD
Trimipramine—Tachycardia—Niacin—atherosclerosis	0.000363	0.00373	CcSEcCtD
Trimipramine—Pruritus—Rosuvastatin—atherosclerosis	0.000362	0.00371	CcSEcCtD
Trimipramine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000359	0.00368	CcSEcCtD
Trimipramine—Feeling abnormal—Lovastatin—atherosclerosis	0.000357	0.00366	CcSEcCtD
Trimipramine—Dyspepsia—Simvastatin—atherosclerosis	0.000357	0.00366	CcSEcCtD
Trimipramine—Anorexia—Niacin—atherosclerosis	0.000355	0.00364	CcSEcCtD
Trimipramine—Decreased appetite—Simvastatin—atherosclerosis	0.000352	0.00362	CcSEcCtD
Trimipramine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00035	0.00359	CcSEcCtD
Trimipramine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00035	0.00359	CcSEcCtD
Trimipramine—Fatigue—Simvastatin—atherosclerosis	0.000349	0.00359	CcSEcCtD
Trimipramine—Anorexia—Pravastatin—atherosclerosis	0.000349	0.00358	CcSEcCtD
Trimipramine—Hypotension—Niacin—atherosclerosis	0.000348	0.00357	CcSEcCtD
Trimipramine—Constipation—Simvastatin—atherosclerosis	0.000347	0.00356	CcSEcCtD
Trimipramine—Urticaria—Lovastatin—atherosclerosis	0.000344	0.00353	CcSEcCtD
Trimipramine—Abdominal pain—Lovastatin—atherosclerosis	0.000343	0.00352	CcSEcCtD
Trimipramine—Body temperature increased—Lovastatin—atherosclerosis	0.000343	0.00352	CcSEcCtD
Trimipramine—Dizziness—Rosuvastatin—atherosclerosis	0.000338	0.00347	CcSEcCtD
Trimipramine—Urticaria—Ezetimibe—atherosclerosis	0.000338	0.00347	CcSEcCtD
Trimipramine—Insomnia—Niacin—atherosclerosis	0.000337	0.00345	CcSEcCtD
Trimipramine—Body temperature increased—Ezetimibe—atherosclerosis	0.000336	0.00345	CcSEcCtD
Trimipramine—Abdominal pain—Ezetimibe—atherosclerosis	0.000336	0.00345	CcSEcCtD
Trimipramine—Paraesthesia—Niacin—atherosclerosis	0.000334	0.00343	CcSEcCtD
Trimipramine—Feeling abnormal—Simvastatin—atherosclerosis	0.000334	0.00343	CcSEcCtD
Trimipramine—Insomnia—Pravastatin—atherosclerosis	0.000331	0.0034	CcSEcCtD
Trimipramine—Somnolence—Niacin—atherosclerosis	0.000331	0.0034	CcSEcCtD
Trimipramine—Paraesthesia—Pravastatin—atherosclerosis	0.000329	0.00338	CcSEcCtD
Trimipramine—Dyspepsia—Niacin—atherosclerosis	0.000328	0.00336	CcSEcCtD
Trimipramine—Dimetindene—HRH1—atherosclerosis	0.000324	0.0549	CrCbGaD
Trimipramine—Decreased appetite—Niacin—atherosclerosis	0.000323	0.00332	CcSEcCtD
Trimipramine—Dyspepsia—Pravastatin—atherosclerosis	0.000323	0.00331	CcSEcCtD
Trimipramine—Rash—Rosuvastatin—atherosclerosis	0.000322	0.00331	CcSEcCtD
Trimipramine—Dermatitis—Rosuvastatin—atherosclerosis	0.000322	0.00331	CcSEcCtD
Trimipramine—Urticaria—Simvastatin—atherosclerosis	0.000322	0.0033	CcSEcCtD
Trimipramine—Abdominal pain—Simvastatin—atherosclerosis	0.00032	0.00329	CcSEcCtD
Trimipramine—Body temperature increased—Simvastatin—atherosclerosis	0.00032	0.00329	CcSEcCtD
Trimipramine—Headache—Rosuvastatin—atherosclerosis	0.00032	0.00329	CcSEcCtD
Trimipramine—HTR2A—endothelium—atherosclerosis	0.000319	0.0347	CbGeAlD
Trimipramine—Decreased appetite—Pravastatin—atherosclerosis	0.000319	0.00327	CcSEcCtD
Trimipramine—Alimemazine—HRH1—atherosclerosis	0.000318	0.0539	CrCbGaD
Trimipramine—Fatigue—Pravastatin—atherosclerosis	0.000316	0.00324	CcSEcCtD
Trimipramine—Constipation—Pravastatin—atherosclerosis	0.000313	0.00322	CcSEcCtD
Trimipramine—Asthenia—Lovastatin—atherosclerosis	0.000311	0.00319	CcSEcCtD
Trimipramine—Pruritus—Lovastatin—atherosclerosis	0.000307	0.00315	CcSEcCtD
Trimipramine—Asthenia—Ezetimibe—atherosclerosis	0.000305	0.00313	CcSEcCtD
Trimipramine—HTR1D—connective tissue—atherosclerosis	0.000304	0.033	CbGeAlD
Trimipramine—Nausea—Rosuvastatin—atherosclerosis	0.000304	0.00312	CcSEcCtD
Trimipramine—Feeling abnormal—Pravastatin—atherosclerosis	0.000302	0.0031	CcSEcCtD
Trimipramine—Pruritus—Ezetimibe—atherosclerosis	0.000301	0.00309	CcSEcCtD
Trimipramine—Diarrhoea—Lovastatin—atherosclerosis	0.000296	0.00304	CcSEcCtD
Trimipramine—Urticaria—Niacin—atherosclerosis	0.000296	0.00303	CcSEcCtD
Trimipramine—HTR2A—blood vessel—atherosclerosis	0.000294	0.032	CbGeAlD
Trimipramine—Abdominal pain—Niacin—atherosclerosis	0.000294	0.00302	CcSEcCtD
Trimipramine—Body temperature increased—Niacin—atherosclerosis	0.000294	0.00302	CcSEcCtD
Trimipramine—Epinastine—HRH1—atherosclerosis	0.000291	0.0493	CrCbGaD
Trimipramine—Urticaria—Pravastatin—atherosclerosis	0.000291	0.00299	CcSEcCtD
Trimipramine—Asthenia—Simvastatin—atherosclerosis	0.000291	0.00298	CcSEcCtD
Trimipramine—Diarrhoea—Ezetimibe—atherosclerosis	0.000291	0.00298	CcSEcCtD
Trimipramine—Abdominal pain—Pravastatin—atherosclerosis	0.00029	0.00297	CcSEcCtD
Trimipramine—Body temperature increased—Pravastatin—atherosclerosis	0.00029	0.00297	CcSEcCtD
Trimipramine—Pruritus—Simvastatin—atherosclerosis	0.000287	0.00294	CcSEcCtD
Trimipramine—Dizziness—Lovastatin—atherosclerosis	0.000287	0.00294	CcSEcCtD
Trimipramine—Dizziness—Ezetimibe—atherosclerosis	0.000281	0.00288	CcSEcCtD
Trimipramine—Diarrhoea—Simvastatin—atherosclerosis	0.000277	0.00285	CcSEcCtD
Trimipramine—Vomiting—Lovastatin—atherosclerosis	0.000275	0.00283	CcSEcCtD
Trimipramine—Mequitazine—HRH1—atherosclerosis	0.000274	0.0464	CrCbGaD
Trimipramine—Rash—Lovastatin—atherosclerosis	0.000273	0.0028	CcSEcCtD
Trimipramine—Dermatitis—Lovastatin—atherosclerosis	0.000273	0.0028	CcSEcCtD
Trimipramine—Headache—Lovastatin—atherosclerosis	0.000271	0.00279	CcSEcCtD
Trimipramine—Vomiting—Ezetimibe—atherosclerosis	0.00027	0.00277	CcSEcCtD
Trimipramine—Dizziness—Simvastatin—atherosclerosis	0.000268	0.00275	CcSEcCtD
Trimipramine—Rash—Ezetimibe—atherosclerosis	0.000268	0.00275	CcSEcCtD
Trimipramine—Dermatitis—Ezetimibe—atherosclerosis	0.000268	0.00275	CcSEcCtD
Trimipramine—Asthenia—Niacin—atherosclerosis	0.000267	0.00274	CcSEcCtD
Trimipramine—Headache—Ezetimibe—atherosclerosis	0.000266	0.00273	CcSEcCtD
Trimipramine—HTR1D—cardiovascular system—atherosclerosis	0.000264	0.0287	CbGeAlD
Trimipramine—Pruritus—Niacin—atherosclerosis	0.000263	0.0027	CcSEcCtD
Trimipramine—Asthenia—Pravastatin—atherosclerosis	0.000263	0.0027	CcSEcCtD
Trimipramine—Pruritus—Pravastatin—atherosclerosis	0.000259	0.00266	CcSEcCtD
Trimipramine—Vomiting—Simvastatin—atherosclerosis	0.000258	0.00264	CcSEcCtD
Trimipramine—Nausea—Lovastatin—atherosclerosis	0.000257	0.00264	CcSEcCtD
Trimipramine—Rash—Simvastatin—atherosclerosis	0.000256	0.00262	CcSEcCtD
Trimipramine—Dermatitis—Simvastatin—atherosclerosis	0.000255	0.00262	CcSEcCtD
Trimipramine—Diarrhoea—Niacin—atherosclerosis	0.000255	0.00261	CcSEcCtD
Trimipramine—Headache—Simvastatin—atherosclerosis	0.000254	0.00261	CcSEcCtD
Trimipramine—Nausea—Ezetimibe—atherosclerosis	0.000252	0.00259	CcSEcCtD
Trimipramine—Diarrhoea—Pravastatin—atherosclerosis	0.000251	0.00257	CcSEcCtD
Trimipramine—Dizziness—Niacin—atherosclerosis	0.000246	0.00253	CcSEcCtD
Trimipramine—Benazepril—MTHFR—atherosclerosis	0.000244	0.0413	CrCbGaD
Trimipramine—Dizziness—Pravastatin—atherosclerosis	0.000242	0.00249	CcSEcCtD
Trimipramine—Nausea—Simvastatin—atherosclerosis	0.000241	0.00247	CcSEcCtD
Trimipramine—Vomiting—Niacin—atherosclerosis	0.000237	0.00243	CcSEcCtD
Trimipramine—Rash—Niacin—atherosclerosis	0.000235	0.00241	CcSEcCtD
Trimipramine—Dermatitis—Niacin—atherosclerosis	0.000234	0.00241	CcSEcCtD
Trimipramine—Headache—Niacin—atherosclerosis	0.000233	0.00239	CcSEcCtD
Trimipramine—Vomiting—Pravastatin—atherosclerosis	0.000233	0.00239	CcSEcCtD
Trimipramine—Rash—Pravastatin—atherosclerosis	0.000231	0.00237	CcSEcCtD
Trimipramine—Dermatitis—Pravastatin—atherosclerosis	0.000231	0.00237	CcSEcCtD
Trimipramine—Headache—Pravastatin—atherosclerosis	0.00023	0.00236	CcSEcCtD
Trimipramine—Nausea—Niacin—atherosclerosis	0.000221	0.00227	CcSEcCtD
Trimipramine—HTR1A—cardiovascular system—atherosclerosis	0.00022	0.0239	CbGeAlD
Trimipramine—Nausea—Pravastatin—atherosclerosis	0.000218	0.00223	CcSEcCtD
Trimipramine—ADRA1A—cardiovascular system—atherosclerosis	0.000203	0.0221	CbGeAlD
Trimipramine—Benazepril—ACE—atherosclerosis	0.000199	0.0337	CrCbGaD
Trimipramine—ABCB1—blood vessel—atherosclerosis	0.000193	0.021	CbGeAlD
Trimipramine—HRH1—connective tissue—atherosclerosis	0.000181	0.0196	CbGeAlD
Trimipramine—ADRA1A—adipose tissue—atherosclerosis	0.000179	0.0195	CbGeAlD
Trimipramine—ADRA2A—connective tissue—atherosclerosis	0.000178	0.0193	CbGeAlD
Trimipramine—Mianserin—HRH1—atherosclerosis	0.000169	0.0285	CrCbGaD
Trimipramine—Propiomazine—HRH1—atherosclerosis	0.000162	0.0275	CrCbGaD
Trimipramine—CYP2C9—cardiovascular system—atherosclerosis	0.000159	0.0173	CbGeAlD
Trimipramine—HTR2A—connective tissue—atherosclerosis	0.000151	0.0164	CbGeAlD
Trimipramine—Nortriptyline—HRH1—atherosclerosis	0.000151	0.0255	CrCbGaD
Trimipramine—Diphenhydramine—HRH1—atherosclerosis	0.000139	0.0236	CrCbGaD
Trimipramine—HRH1—adipose tissue—atherosclerosis	0.000139	0.0151	CbGeAlD
Trimipramine—Methotrimeprazine—HRH1—atherosclerosis	0.000139	0.0235	CrCbGaD
Trimipramine—Promethazine—HRH1—atherosclerosis	0.000137	0.0231	CrCbGaD
Trimipramine—ADRA2A—adipose tissue—atherosclerosis	0.000136	0.0148	CbGeAlD
Trimipramine—Doxepin—HRH1—atherosclerosis	0.000135	0.0229	CrCbGaD
Trimipramine—Orphenadrine—HRH1—atherosclerosis	0.000132	0.0223	CrCbGaD
Trimipramine—HTR2A—cardiovascular system—atherosclerosis	0.000131	0.0143	CbGeAlD
Trimipramine—CYP2C19—liver—atherosclerosis	0.000127	0.0138	CbGeAlD
Trimipramine—ADRA1A—liver—atherosclerosis	0.000126	0.0136	CbGeAlD
Trimipramine—Desipramine—HRH1—atherosclerosis	0.000124	0.021	CrCbGaD
Trimipramine—Promazine—HRH1—atherosclerosis	0.00012	0.0203	CrCbGaD
Trimipramine—Chlorpromazine—HRH1—atherosclerosis	0.000106	0.0179	CrCbGaD
Trimipramine—Imipramine—HRH1—atherosclerosis	0.000105	0.0178	CrCbGaD
Trimipramine—Amitriptyline—HRH1—atherosclerosis	0.000105	0.0177	CrCbGaD
Trimipramine—CYP2C9—liver—atherosclerosis	9.86e-05	0.0107	CbGeAlD
Trimipramine—ABCB1—cardiovascular system—atherosclerosis	8.61e-05	0.00935	CbGeAlD
Trimipramine—HTR2A—liver—atherosclerosis	8.12e-05	0.00882	CbGeAlD
Trimipramine—ABCB1—adipose tissue—atherosclerosis	7.59e-05	0.00824	CbGeAlD
Trimipramine—CYP3A4—liver—atherosclerosis	7.52e-05	0.00817	CbGeAlD
Trimipramine—CYP2D6—liver—atherosclerosis	7.4e-05	0.00804	CbGeAlD
Trimipramine—Oxcarbazepine—ALB—atherosclerosis	6.2e-05	0.0105	CrCbGaD
Trimipramine—ABCB1—liver—atherosclerosis	5.32e-05	0.00578	CbGeAlD
Trimipramine—Acepromazine—ALB—atherosclerosis	4.68e-05	0.00793	CrCbGaD
Trimipramine—Clomipramine—ALB—atherosclerosis	3.56e-05	0.00603	CrCbGaD
Trimipramine—Nortriptyline—ALB—atherosclerosis	3.48e-05	0.00589	CrCbGaD
Trimipramine—Chlorpromazine—ALB—atherosclerosis	2.44e-05	0.00413	CrCbGaD
Trimipramine—Amitriptyline—ALB—atherosclerosis	2.41e-05	0.00409	CrCbGaD
Trimipramine—CYP2C9—Metabolism—APOB—atherosclerosis	4.25e-06	5.38e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—GPX1—atherosclerosis	4.23e-06	5.36e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CETP—atherosclerosis	4.23e-06	5.35e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CD36—atherosclerosis	4.22e-06	5.35e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	4.2e-06	5.32e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—INS—atherosclerosis	4.2e-06	5.31e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—NOS3—atherosclerosis	4.19e-06	5.31e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	4.18e-06	5.3e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	4.18e-06	5.29e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	4.17e-06	5.28e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	4.17e-06	5.28e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.17e-06	5.27e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—F2—atherosclerosis	4.15e-06	5.25e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—INS—atherosclerosis	4.13e-06	5.23e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—GSTM1—atherosclerosis	4.13e-06	5.23e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CCL2—atherosclerosis	4.13e-06	5.23e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CD36—atherosclerosis	4.12e-06	5.22e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—INS—atherosclerosis	4.12e-06	5.22e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—ALB—atherosclerosis	4.12e-06	5.22e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	4.09e-06	5.18e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—LPL—atherosclerosis	4.09e-06	5.18e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	4.06e-06	5.15e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IGF1—atherosclerosis	4.06e-06	5.14e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CCL2—atherosclerosis	4.06e-06	5.13e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—LPL—atherosclerosis	4.05e-06	5.13e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	4.05e-06	5.13e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.05e-06	5.13e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—INS—atherosclerosis	4.04e-06	5.12e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—STAT3—atherosclerosis	4.01e-06	5.08e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—MTHFR—atherosclerosis	4e-06	5.07e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	4e-06	5.06e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	3.99e-06	5.06e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—GPX1—atherosclerosis	3.99e-06	5.05e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.99e-06	5.05e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	3.98e-06	5.04e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	3.97e-06	5.03e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—GPX1—atherosclerosis	3.96e-06	5.01e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—NOS3—atherosclerosis	3.94e-06	4.99e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PPARA—atherosclerosis	3.93e-06	4.97e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	3.91e-06	4.95e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—MTHFR—atherosclerosis	3.91e-06	4.95e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CD36—atherosclerosis	3.89e-06	4.92e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	3.86e-06	4.88e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	3.85e-06	4.88e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CD36—atherosclerosis	3.85e-06	4.88e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PPARA—atherosclerosis	3.83e-06	4.85e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.83e-06	4.85e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.82e-06	4.84e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—AGT—atherosclerosis	3.8e-06	4.82e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.8e-06	4.81e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.79e-06	4.8e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.79e-06	4.79e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.76e-06	4.76e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—APOE—atherosclerosis	3.73e-06	4.72e-05	CbGpPWpGaD
Trimipramine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	3.72e-06	4.71e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.72e-06	4.71e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.72e-06	4.71e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.72e-06	4.7e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—AGT—atherosclerosis	3.71e-06	4.7e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.7e-06	4.68e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.7e-06	4.68e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CAV1—atherosclerosis	3.69e-06	4.68e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—APOA1—atherosclerosis	3.68e-06	4.66e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.68e-06	4.66e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.68e-06	4.66e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	3.66e-06	4.64e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—MTHFR—atherosclerosis	3.65e-06	4.62e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—APOE—atherosclerosis	3.64e-06	4.61e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.63e-06	4.6e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.62e-06	4.59e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.61e-06	4.58e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PPARA—atherosclerosis	3.61e-06	4.57e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.6e-06	4.56e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CAV1—atherosclerosis	3.6e-06	4.56e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—APOA1—atherosclerosis	3.6e-06	4.55e-05	CbGpPWpGaD
Trimipramine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.59e-06	4.55e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PPARA—atherosclerosis	3.58e-06	4.53e-05	CbGpPWpGaD
Trimipramine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.57e-06	4.53e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.55e-06	4.49e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	3.54e-06	4.48e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.54e-06	4.48e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.52e-06	4.45e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—AGT—atherosclerosis	3.5e-06	4.43e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	3.48e-06	4.41e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—AGT—atherosclerosis	3.47e-06	4.39e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.45e-06	4.37e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	3.45e-06	4.37e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—APOE—atherosclerosis	3.43e-06	4.34e-05	CbGpPWpGaD
Trimipramine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	3.42e-06	4.33e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.41e-06	4.31e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—APOE—atherosclerosis	3.4e-06	4.3e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CAV1—atherosclerosis	3.4e-06	4.3e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	3.39e-06	4.29e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—APOA1—atherosclerosis	3.39e-06	4.29e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	3.38e-06	4.28e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	3.37e-06	4.26e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CAV1—atherosclerosis	3.37e-06	4.26e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.36e-06	4.26e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	3.36e-06	4.26e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—APOA1—atherosclerosis	3.36e-06	4.25e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.35e-06	4.24e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.33e-06	4.21e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.31e-06	4.19e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	3.3e-06	4.17e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.28e-06	4.16e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.27e-06	4.14e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	3.27e-06	4.13e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.26e-06	4.13e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.25e-06	4.12e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PPARG—atherosclerosis	3.25e-06	4.11e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.25e-06	4.11e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.21e-06	4.07e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.21e-06	4.06e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	3.2e-06	4.06e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—INS—atherosclerosis	3.18e-06	4.03e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	3.17e-06	4.01e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PPARG—atherosclerosis	3.17e-06	4.01e-05	CbGpPWpGaD
Trimipramine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	3.15e-06	3.99e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	3.15e-06	3.98e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	3.13e-06	3.96e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	3.12e-06	3.94e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—INS—atherosclerosis	3.11e-06	3.93e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	3.11e-06	3.93e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—IL6—atherosclerosis	3.11e-06	3.93e-05	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.1e-06	3.93e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	3.1e-06	3.92e-05	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.1e-06	3.92e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.09e-06	3.92e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.07e-06	3.88e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.06e-06	3.87e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.05e-06	3.86e-05	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	3.04e-06	3.85e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	3.02e-06	3.82e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	3.01e-06	3.8e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.99e-06	3.79e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.99e-06	3.79e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PPARG—atherosclerosis	2.99e-06	3.78e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.98e-06	3.77e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	2.96e-06	3.75e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PPARG—atherosclerosis	2.96e-06	3.75e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.95e-06	3.74e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—INS—atherosclerosis	2.93e-06	3.71e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.92e-06	3.7e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.92e-06	3.7e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.92e-06	3.7e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—ALB—atherosclerosis	2.92e-06	3.7e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.91e-06	3.68e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—INS—atherosclerosis	2.9e-06	3.68e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.9e-06	3.67e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	2.88e-06	3.64e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.88e-06	3.64e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.87e-06	3.64e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	2.87e-06	3.64e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.87e-06	3.63e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.86e-06	3.63e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.86e-06	3.62e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—ALB—atherosclerosis	2.85e-06	3.61e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	2.85e-06	3.61e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.85e-06	3.6e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.84e-06	3.6e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.83e-06	3.58e-05	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.82e-06	3.58e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.82e-06	3.57e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.82e-06	3.57e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.82e-06	3.56e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.81e-06	3.56e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.8e-06	3.55e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—APOB—atherosclerosis	2.8e-06	3.55e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—NOS3—atherosclerosis	2.79e-06	3.53e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.78e-06	3.52e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.77e-06	3.51e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.77e-06	3.5e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.76e-06	3.49e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.76e-06	3.49e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—NOS3—atherosclerosis	2.73e-06	3.45e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.72e-06	3.45e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	2.72e-06	3.45e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—ALB—atherosclerosis	2.68e-06	3.4e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—LPL—atherosclerosis	2.67e-06	3.39e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—ALB—atherosclerosis	2.66e-06	3.37e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.65e-06	3.36e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.64e-06	3.35e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	2.64e-06	3.34e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.63e-06	3.32e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.62e-06	3.31e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.61e-06	3.3e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GPX1—atherosclerosis	2.61e-06	3.3e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.6e-06	3.3e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.58e-06	3.27e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.58e-06	3.27e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.58e-06	3.26e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.57e-06	3.26e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—NOS3—atherosclerosis	2.57e-06	3.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.56e-06	3.25e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.56e-06	3.24e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTGS2—atherosclerosis	2.55e-06	3.23e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—NOS3—atherosclerosis	2.55e-06	3.22e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CD36—atherosclerosis	2.54e-06	3.22e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.53e-06	3.2e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.51e-06	3.18e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTGS2—atherosclerosis	2.49e-06	3.16e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.47e-06	3.13e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.46e-06	3.12e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.43e-06	3.08e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.42e-06	3.06e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.41e-06	3.05e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.4e-06	3.03e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.39e-06	3.03e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.37e-06	3.01e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARA—atherosclerosis	2.36e-06	2.99e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.35e-06	2.98e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.35e-06	2.97e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.35e-06	2.97e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.33e-06	2.95e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—AGT—atherosclerosis	2.29e-06	2.9e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.25e-06	2.84e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—APOE—atherosclerosis	2.24e-06	2.84e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CAV1—atherosclerosis	2.22e-06	2.81e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—APOA1—atherosclerosis	2.22e-06	2.8e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.18e-06	2.76e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	2.16e-06	2.74e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.09e-06	2.64e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.08e-06	2.63e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.02e-06	2.56e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	2e-06	2.53e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.99e-06	2.52e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARG—atherosclerosis	1.95e-06	2.47e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.93e-06	2.44e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.92e-06	2.43e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—INS—atherosclerosis	1.91e-06	2.42e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.84e-06	2.32e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.83e-06	2.32e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.81e-06	2.29e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.8e-06	2.29e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.8e-06	2.28e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.77e-06	2.24e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ALB—atherosclerosis	1.76e-06	2.22e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.69e-06	2.14e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.68e-06	2.13e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.67e-06	2.11e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.66e-06	2.1e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.64e-06	2.08e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	2.06e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.54e-06	1.94e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.51e-06	1.92e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—AKT1—atherosclerosis	1.28e-06	1.62e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—AKT1—atherosclerosis	1.25e-06	1.59e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.18e-06	1.49e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.17e-06	1.48e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—AKT1—atherosclerosis	7.72e-07	9.77e-06	CbGpPWpGaD
